References

• 2012Model Transparency and Validation802 cited
• 2012Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1767 cited
• 2016Assessing the Gold Standard — Lessons from the History of RCTs663 cited
• 2020Using Experts` Opinions Through Delphi Technique476 cited
• 2012Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7467 cited
• 2007Assessing the economic challenges posed by orphan drugs279 cited
• 2011Pricing and reimbursement of orphan drugs: the need for more transparency261 cited
• 2016Meta‐analysis of few small studies in orphan diseases190 cited
• 2012Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?171 cited
• 2016Estimating Health-State Utility for Economic Models in Clinical Studies: An ISPOR Good Research Practices Task Force Report159 cited
• 2013Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries122 cited
• 2016Social/economic costs and health-related quality of life in patients with rare diseases in Europe121 cited
• 2017Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients’ health needs?